New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy

Area of Science:

• Oncology
• Cell Biology
• Genetics

Background:

• Aneuploidy, characterized by abnormal chromosome numbers, is a common feature in cancer cells.
• Defects in chromosome segregation, including kinetochore-microtubule attachments, centrosome abnormalities, spindle assembly checkpoint (SAC) dysfunction, and cohesion defects, lead to aneuploidy.
• While aneuploidy can confer a proliferative advantage, excessive levels can be detrimental to cancer cell survival.

Purpose of the Study:

• To review the therapeutic potential of targeting chromosome missegregation in aneuploid cancers.
• To explore novel agents that induce chromosome missegregation and aneuploidy.
• To discuss the combination of these agents with existing antineoplastic therapies.

Main Methods:

• Literature review of existing research on aneuploidy and chromosome segregation pathways.
• Analysis of preclinical and clinical data on agents targeting chromosome missegregation.
• Exploration of therapeutic strategies involving SAC inhibitors and agents affecting centrosome fidelity.

Main Results:

• Aneuploidy is a critical hallmark of cancer, driven by various chromosome segregation defects.
• Targeting proteins and pathways involved in chromosome segregation presents a viable therapeutic strategy.
• Agents that induce chromosome missegregation are under active investigation and show therapeutic promise.

Conclusions:

• Exploiting chromosome missegregation pathways offers a novel approach to cancer therapy.
• Agents inducing aneuploidy, such as SAC inhibitors, are being developed for clinical use.
• Combining these novel agents with other antineoplastic drugs may enhance treatment efficacy.